Supplementary Tables S1-S10 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer

Table S1. Negative control samples used for LOB determination; Table S2. Quality of sequencing of BRAF and RAS genes; Table S3. REMARK checklist; Table S4. Patient characteristics; Table S5. Safety profiles; Table S6. Adverse event data; Table S7. Association of detectable ctDNA at baseline and patient characteristics; Table S8. Response in the LctDNA and HctDNA group; Table S9. BRAF V600E mutation analysis in patient 13; Table S10. Clinical trials comparing anti-EGFR and anti-VEGF in first-line therapy of RAS WT mCRC.